Outcomes of romiplostim for chemotherapy-induced thrombocytopenia (CIT) in solid tumors (20220113)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/1000000067
• EU PAS number:
  EUPAS1000000067
• Study ID:
  1000000067
• Official title and acronym:
  Outcomes of romiplostim for chemotherapy-induced thrombocytopenia (CIT) in solid tumors (20220113)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study status:
  Planned

Research institution and networks

Institutions

Amgen

United States

Study timelines

Date when funding contract was signed

Planned: 10/05/2024

Study start date

Planned: 15/09/2024

Data analysis start date

Planned: 19/02/2025

Date of final study report

Planned: 31/07/2025

Sources of funding

Pharmaceutical company and other private sector 

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Non-EU RMP only